Correction: Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Whole-body diffusion-weighted imaging's total diffusion volume as a significant prognostic indicator for survival in metastatic castration-resistant prostate cancer

  • By

  • Luca D’Erme

  • Giacomo Avesani

  • Luca Russo

  • Silvia Bottazzi

  • Brandon Whitcher

  • Antonio Candito

  • Robby Emsley

  • Davide Meo

  • Alec Paschalis

  • Adam Sharp

  • Nina Tunariu

  • Dow-Mu Koh

  • September 30, 2026

Share

  • 1

    The article is a correction to a previously published study in European Radiology.

  • 2

    The author's name was incorrectly listed as Doh-Mu Koh instead of Dow-Mu Koh.

  • 3

    The publication date of the original article was 13 August 2026.

  • 4

    The DOI for the original article is 10.1007/s00330-026-12792-1.

  • 5

    The Prostate Cancer UK grant number was incorrectly reported as R746, and the correct number is RIA-18-ST2-023.

Original Source(s)

Correction: Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer

  • by Luca D’Erme, Giacomo Avesani, Luca Russo, Silvia Bottazzi, Brandon Whitcher, Antonio Candito, Robby Emsley, Davide Meo, Alec Paschalis, Adam Sharp, Nina Tunariu, Dow-Mu Koh

  • September 30, 2026

Related Content

Expanding surgical options for liver cancer and liver metastases

Advances in minimally invasive surgery and liver-directed therapies at UCI Health offer new treatment for complex liver malignancies.

  • October 14, 2026

  • 2 min
EQUIPOISE: EQUivalence In Prostate cancer treatment: surgery Or radiotherapy? An Intention-to-treat Survival analysis from real-world Evidence

The association between MGMT expression and outcome in H3 G34-mutant diffuse hemispheric glioma is robust to adjustment for pre-analytic and technical variables